Group 1 - The transaction involves the acquisition of assets for a total price of 335 million yuan, with 301 million yuan in stock and 33.79 million yuan in cash [1] - After the transaction, Yijie Medical will become a wholly-owned subsidiary of the company [1] - The fundraising amount is set at 134 million yuan, with a share issuance price of 57.35 yuan per share, aimed at supporting the development of drug balloon dilation catheters and covering transaction-related costs [1] Group 2 - Maipu Medical is a high-tech enterprise focused on developing high-performance implantable medical devices using advanced manufacturing technology [2] - The company is the only domestic entity in the neurosurgery field with a comprehensive range of implantable medical devices, including artificial dura mater patches and absorbable regenerated oxidized cellulose [1][2] - Yijie Medical specializes in the research, design, and sales of neuro-interventional medical devices, with established partnerships with over 200 distributors and coverage in more than 200 top-tier hospitals nationwide [1][2] Group 3 - The collaboration between Maipu Medical and Yijie Medical will enhance the marketing efforts in neurology departments by integrating their distribution channels and promotional systems [2] - Maipu Medical has extensive R&D experience and a leading technical platform in the field of biocomposite materials, while Yijie Medical has a deep understanding of the needs for neuro-interventional surgical devices [2] - The acquisition is expected to expand product categories, broaden sales regions, and strengthen the strategic synergy between biocomposite technology and neuro-interventional medical devices, ultimately improving the overall profitability of the listed company [2]

Core Viewpoint - The company plans to acquire 100% equity of Yijie Medical for a total transaction price of 334.85 million yuan, aiming to expand its product offerings in the neuro-interventional medical device sector [1] Group 1: Acquisition Details - The acquisition will be executed through a combination of share issuance and cash payment [1] - Yijie Medical specializes in the research, design, and sales of medical devices in the neuro-interventional field, including treatment and access products [1] Group 2: Market Position and Synergies - Yijie Medical has established partnerships with over 200 distributors and its products are available in more than 200 top-tier hospitals across the country [1] - The target company's primary customers are neurology departments in hospitals, which overlap significantly with the company's existing customer base [1] - Post-acquisition, the company aims to leverage the combined distribution channels and marketing systems to enhance sales efficiency in neurology departments [1] Group 3: Technological and R&D Advantages - The company possesses extensive R&D experience and a strong technical foundation in medical devices for neurology [1] - The acquisition will enable the company to extend its expertise in biocomposite materials from the implantation field to the interventional field, enhancing its R&D capabilities in interventional biomaterials [1]